What is RNAZ's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.03B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RNAZ?

P/E (TTM) is n/a and 52-week range is $1.52 to $20.99 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RNAZ figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RNAZ?

The company profile lists net income (TTM) near $-50M, EPS (TTM) near $-47.00 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Transcode Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 1.1M shares outstanding, ISIN US89357L5012 when available from company profile and filing metadata.

Transcode Therapeutics Inc

$RNAZ

Health Care · Biotechnology

IR Run Scenarios

$1.86

+8.77%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2021-04-28. The company is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The firm is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Employees

Website

www.transcodetherapeutics.com/

IPO

2021-04-28

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)